Morgan Stanley
ACOR

Morgan Stanley’s Acorda Therapeutics ACOR Stock Holding History

Morgan Stanley’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,137
Closed -$15K – 8094
2024
Q1 		$15K Sell
1,137
-1,215
-52% -$17.6K ﹤0.01% 6570
2023
Q4 		$35.5K Buy
2,352
+1,176
+100% +$13.3K ﹤0.01% 6473
2023
Q3 		$17.6K Sell
1,176
-100
-8% -$1.51K ﹤0.01% 6527
2023
Q2 		$16.6K Buy
1,276
+797
+166% +$9.47K ﹤0.01% 6629
2023
Q1 		$5.61K Buy
479
+230
+92% +$3.82K ﹤0.01% 7024
2022
Q4 		$3.82K Sell
249
-86
-26% -$1K ﹤0.01% 7220
2022
Q3 		$1K Buy
335
+67
+25% +$560 ﹤0.01% 7650
2022
Q2 		$2K Buy
268
+28
+12% +$498 ﹤0.01% 7630
2022
Q1 		$8K Sell
240
-13
-5% -$511 ﹤0.01% 7479
2021
Q4 		$11K Buy
253
+52
+26% +$3.58K ﹤0.01% 7455
2021
Q3 		$19K Sell
201
-921
-82% -$76.4K ﹤0.01% 7124
2021
Q2 		$107K Buy
1,122
+1,075
+2,287% +$94K ﹤0.01% 6326
2021
Q1 		$4K Sell
47
-68
-59% -$8.35K ﹤0.01% 7176
2020
Q4 		$9K Sell
115
-10
-8% -$919 ﹤0.01% 6670
2020
Q3 		$8K Sell
125
-162
-56% -$12.2K ﹤0.01% 6346
2020
Q2 		$25K Sell
287
-1,645
-85% -$174K ﹤0.01% 5953
2020
Q1 		$215K Sell
1,932
-24
-1% -$4.72K ﹤0.01% 4836
2019
Q4 		$479K Buy
1,956
+585
+43% +$148K ﹤0.01% 4946
2019
Q3 		$472K Sell
1,371
-678
-33% -$369K ﹤0.01% 4705
2019
Q2 		$1.89M Buy
2,049
+1,381
+207% +$1.7M ﹤0.01% 3820
2019
Q1 		$1.06M Buy
668
+68
+11% +$123K ﹤0.01% 4063
2018
Q4 		$1.12M Sell
600
-433
-42% -$942K ﹤0.01% 4188
2018
Q3 		$2.44M Sell
1,033
-802
-44% -$2.48M ﹤0.01% 3852
2018
Q2 		$6.32M Buy
1,835
+77
+4% +$236K ﹤0.01% 2885
2018
Q1 		$4.99M Sell
1,758
-2,598
-60% -$7.78M ﹤0.01% 3028
2017
Q4 		$11.2M Buy
4,356
+3,706
+570% +$10.5M ﹤0.01% 2294
2017
Q3 		$1.85M Sell
650
-641
-50% -$1.69M ﹤0.01% 3959
2017
Q2 		$3.05M Buy
1,291
+266
+26% +$527K ﹤0.01% 3380
2017
Q1 		$2.58M Sell
1,025
-2,105
-67% -$6.06M ﹤0.01% 3582
2016
Q4 		$7.06M Buy
3,130
+848
+37% +$2.02M ﹤0.01% 2632
2016
Q3 		$5.72M Sell
2,282
-1,415
-38% -$4.22M ﹤0.01% 2537
2016
Q2 		$11.3M Buy
3,697
+87
+2% +$283K ﹤0.01% 1884
2016
Q1 		$11.5M Buy
3,610
+3,203
+787% +$13.3M ﹤0.01% 1751
2015
Q4 		$2.09M Buy
407
+89
+28% +$389K ﹤0.01% 3453
2015
Q3 		$1.01M Buy
318
+199
+167% +$772K ﹤0.01% 4097
2015
Q2 		$476K Sell
119
-3,960
-97% -$15.3M ﹤0.01% 4748
2015
Q1 		$16.3M Buy
4,079
+3,467
+567% +$15.9M 0.01% 1624
2014
Q4 		$3M Sell
612
-403
-40% -$1.73M ﹤0.01% 3201
2014
Q3 		$4.13M Sell
1,015
-995
-50% -$3.73M ﹤0.01% 2793
2014
Q2 		$8.13M Buy
2,010
+1,432
+248% +$5.84M ﹤0.01% 2217
2014
Q1 		$2.63M Sell
578
-2,004
-78% -$8.1M ﹤0.01% 3187
2013
Q4 		$9.05M Buy
2,582
+1,728
+202% +$6.74M ﹤0.01% 2032
2013
Q3 		$3.5M Buy
854
+114
+15% +$491K ﹤0.01% 2765
2013
Q2 		$2.93M Buy
+740
New +$3.05M ﹤0.01% 2827

Other funds holding ACOR

Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Morgan Stanley's ACOR Position: Q2 2024 in Review

Morgan Stanley sold out of Acorda Therapeutics (ACOR) in Q2 2024, closing a stake of 1,137 shares — an estimated $15K sold.

Morgan Stanley first reported a position in ACOR in Q2 2013 and held it in 44 quarters. The position peaked at $16.3M in Q1 2015. 2 funds tracked by Wall St. Rank hold ACOR as of Q2 2024.

  • Morgan Stanley reported no remaining Acorda Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Morgan Stanley sold 1,137 Acorda Therapeutics shares in Q2 2024, an estimated $15K.
  • Morgan Stanley first reported a position in Acorda Therapeutics in Q2 2013 and held it in 44 quarters.
  • Morgan Stanley's Acorda Therapeutics position peaked at $16.3M in Q1 2015.
  • 2 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q2 2024.

Based on Morgan Stanley's 13F filing for Q2 2024, filed 14 Aug 2024.